EU's CHMP considers manufacturing issues with Genzyme products
This article was originally published in Scrip
Executive Summary
The EU's CHMP has concluded that a faulty pump at Genzyme's Flanders facility in Geel, Belgium, has not contaminated any batches the company's treatment for Pompe disease, Myozyme (alglucosidase alfa), which is produced there.